BELLUS Health Inc (BLU)

[Power of Emouna]

Yes way oversold & undervalued stock!

Stock lost over 90% of its value in 1 week. Way oversold! Undervalued imo!!!

Symbol is BLU Montreal, Canada based company trading on the NASDAQ & TSE.

Insiders bought over $494,000 worth of shares in the last week + another $33,000 on July 14, 2020 for a total of $527,000 since the drastic drop. Over half million dollars of insider buys in just one week! That is huge!!!

Larochelle Pierre $206,250 on July 13, 2020

Bellini Francesco $151,704.90 on July 06, 2020.

Other purchase!

Bellini Francesco $136,470 on July 06, 2020


https://mobile.twitter.com/Vqle280z/status/1282871401465217024/photo/2

MUST WATCH

They have solid cash assets!


BELLUS Health Reports Full Year 2019 Financial Results

Cash Position: As of December 31, 2019, the Company had available cash, cash equivalents and short-term investments totalling C$116,884,000 (US$89,980,000), compared to C$48,906,000 (US$35,863,000) as at December 31, 2018.

Here is a direct link to the financial report:
https://ir.bellushealth.com/news-releases/news-release-details/bellus-health-reports-full-year-2019-financial-results-and


Solid company that admittedly had a setback on the FDA phase trial. CEO came out and stated they still know their product works but not at the limited threshold of the study. They will push for another phase 2 in 4th quarter and the stock will rebound hard much higher then $12 price before the crash if phase 2 is successful this time. We could see $20++ imo with a successful phase 2. Way oversold and undervalued down here. Go $BLU$

In the RELIEF trial, we observed data that we believe is competitive within the P2X3 class, including the reduction in cough frequency shown in patients with higher cough counts and a low taste effect. While we had hoped to see more response in the lower cough patients, BLU-5937 and other P2X3 antagonists may have the most benefit in patients with a greater disease burden,” said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. “We believe the Phase 2 data support moving BLU-5937 forward into an adaptive Phase 2b trial enriched for higher cough count patients. We expect to begin this trial in the fourth quarter of 2020.”

https://www.otcmarkets.com/stock/BLU/news/story?e&id=1637916